GE HealthCare Technologies Inc美股招股说明书(2025-06-03版)

$% Senior Notes due 20 “Description of Notes—Optional Redemption.” If we experience a change of control repurchase event with respect to a series of notes, we may be required to offer topurchase such series of notes from their holders. See “Description of Notes—Purchase of Notes upon a Change of Control Repurchase Event.”We expect to use the net proceeds from this offering, together with cash on hand, to repay the $1,500million aggregate principal amount outstanding of our5.600% senior notes due 2025 (the “2025 notes”) and pay accrued interest, related premiums, fees, and expenses in connection therewith. Pending the final application ofthe net proceeds of this offering, we may use such proceeds temporarily for general corporate purposes. See “Use of Proceeds.”The notes will be our senior unsecured obligations and will rank equally in right of payment with all of our other senior unsecured indebtedness, including our other outstanding senior notes. The notes will be issued in minimum denominations of $2,000 and in integral multiples of $1,000 in excess thereof.The notes will not be listed on any securities exchange.Investing in the notes involves risks that are described in the “Risk Factors” section of this prospectus supplementbeginning on pageS-5and in our latest Annual Report onForm10-K,which is incorporated by reference into this prospectus upon the adequacy or accuracy of this prospectus supplement or the related prospectus. Any representation to the contrary is a criminal offense.Initialpublicofferingprice(1)UnderwritingdiscountsProceeds,beforeexpenses,tous %$%$%$%$ $$ The underwriters expect to deliver the notes to purchasers in book-entry form only through the facilities of The Depository Trust Company (“DTC”), including itsparticipants Clearstream Banking S.A. (“Clearstream”) and Euroclear Bank SA/NV (“Euroclear”), against payment in New York, New York on or about Joint Book-Running ManagersCitigroupJ.P. MorganMorgan Stanley Legal Matters secondary market generally are required to settle in one business day unless the parties to that trade expressly agree otherwise. Accordingly, purchaserswho wish to trade the notes on any date prior to one business day before the settlement date will be required, by virtue of the fact that the notes initiallywill settle in T+, to specify an alternative settlement cycle at the time of any such trade to prevent failed settlement and should consult their own accompanying prospectus or in any free writing prospectus filed with the SEC and we take no responsibility for any other information that others maygive you. This prospectus supplement and the accompanying prospectus incorporate by reference important business and financial information about us together with the additional information below under the headings “Where You Can Find More Information” and “Incorporation by Reference.” Theinformation contained in this prospectus supplement and the accompanying prospectus is accurate only as of the date of this prospectus supplement. If there is any inconsistency between the information in this prospectus supplement and the accompanying prospectus or any document incorporatedherein or therein by reference, you should rely on the information in this prospectus supplement.Unless the context otherwise requires, references in this prospectus supplement to the “Company,” “GE HealthCare,” “we,” “us,” and “our” referto GE HealthCare Technologies Inc. and its direct and indirect subsidiaries.References herein to “$” and “dollars” are to the lawful currency of the United States. The financial information presented or incorporated byreference in this prospectus supplement and the accompanying prospectus has been prepared in accordance with Generally Accepted AccountingPrinciples in the United States (“GAAP”). particular, Edison is a trademark licensed to us from the Charles Edison Fund. This prospectus supplement contains or incorporates by reference various historical and projected information concerning our industry, themarkets in which we participate, and our positions in these markets. Some of this information is from industry publications and other third-partysources, and other information is from our own analysis of data received from these third-party sources, our own internal data, and market research that discussed in these forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially fromthose projected, anticipated, or implied in the forward-looking statements. You should read this prospectus, and any accompanying prospectus completely and with the understanding that actual future results may be materially different from expectations. All forward-looking statements made inthis prospectus, any accompanying prospectus supplement, and the documents incorporated or deemed to be incorporated by reference herein or therein are qualified by these cautionary statements. In particular, in